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OBJECTIVES: To compare observational data with a
large clinical study (MUCOSA) which showed that miso-
prostol reduced NSAID complication rates by 40% in pa-
tients with arthritis. To measure the cost of prescribing,
endoscopy and hospitalizations for patients receiving non-
steroidal anti-inflammatory drugs (NSAIDs) and estimate
the cost-effectiveness of misoprostol in routine practice.
METHODS: A cohort study using all patients in the Tay-
side region that received NSAIDs and anti-ulcer drugs be-
tween 1989 and 1995. Thirty-day treatment was esti-
mated from the cost of the NSAID plus endoscopies plus
hospitalization for GI events. Costs of hospitalizations
and endoscopic procedures were obtained from Scottish
Information and Statistics Division for 1997.
RESULTS: Among 54,807 eligible patients the risk ad-
justed rates of hospitalization for gastrointestinal diag-
noses were 50% lower on Arthrotec (a fixed combination
of misoprostol and diclofenac) than on diclofenac alone.
Statistically significant risk factors were: a prior history
of gastrointestinal events (p  0.001), a prior history of
cardiovascular events (p  0.001), increasing age (p 
0.001), social deprivation score (p  0.072), concurrent
exposure to anti-ulcer drugs (p  0.001) or steroids (p 
0.001) and type and dose of NSAID (p  0.001 and p 
0.047 respectively). Only nabumatone had a lower event
rate than Arthrotec, but at a higher expected cost. Ar-
throtec had lower 30 day treatment and complication
costs than diclofenac alone in high risk patients (e.g., £52
vs £86 for a patient aged 80–89 with a prior history of
GI events) but not in low risk patients (e.g., £16.50 vs
£15 for a patient aged 50–59 with no prior GI events).
CONCLUSIONS: There was close agreement between
this observational study and the MUCOSA study on the
extent to which the prophylactic use of misoprostol re-
duced NSAID associated gastrointestinal complications.
The combination of misoprostol with diclofenac should
reduce thirty day treatment and complication costs in
high risk patients, in comparison with diclofenac alone.
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OBJECTIVES: To investigate the cost-effectiveness of
high dose IV omeprazole as an adjuvant therapy to endo-
scopic hemostasis for prevention of early ulcer rebleeding
from a hospital perspective. A randomized, placebo-con-
trolled clinical trial was conducted previously in a local
hospital to study the effects of high dose IV omeprazole in-
fusion on patient outcomes after endoscopic ulcer hemo-
stasis. Although the interim data suggested that IV ome-
prazole significantly decreased the rate of early rebleeding
that occurred 72 hours after therapy, the cost implication
of this therapy has not been examined.
METHODS: The data of 157 patients who completed the
above study was analyzed. The percentages of patients who
experienced early rebleeding were obtained from medical
records. The health care resources consumed by each pa-
tient during the first 72 hours post endoscopic hemostasis
were also retrieved from their records and studied.
RESULTS: Four of 80 (5%) patients in the omeprazole
group and 17 of 77 (22%) patients from the placebo
group had rebleeding within 72 hrs after endoscopy and
required further treatment. The treatment cost within 72
hours post endoscopy of the IV omeprazole group was
lower than that of the placebo group (HK$1312 per pa-
tient vs. $3223 per patient, 1 US  7.8 HK). The cost-
effectiveness ratios for the omeprazole group and placebo
group were $9,946 and $12,821, respectively, per early re-
bleeding episode prevented.
CONCLUSIONS: High dose omeprazole is more cost-
effective in preventing early ulcer rebleeding than placebo
after endoscopic hemostasis.
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OBJECTIVES: To determine the economical and clinical
impact of pharmacists’ interventions in ambulatory care
within the context of a prescribing error of Nonsteroidal
Anti-Inflammatory Drugs (NSAIDs).
METHOD: A national survey was carried out in 900
town pharmacies during 12 weeks to record all prescrip-
tions with an anomaly like contraindication, interaction
which could be dangerous for the patient. We used a deci-
sion analysis to compare two strategies, with or without a
systematic pharmacist’s intervention before a prescription
of NSAIDs. The outcome was upper gastrointestinal side
effects of NSAID therapy (peptic ulcer and complications)
and we used a prescribing errors rate varying between
0,5% to 2% to estimate the costs savings and to measure
the occurrence of peptic ulcer avoided. Computer simula-
tion was performed with Tree Age 3.0.
RESULTS: 446 cases of NSAIDs prescription errors were
notified including combination of NSAIDs, NSAIDs over-
dose and NSAIDs prescription with risk factors like peptic
